/
Other
Efficacy and Safety
223
Pipeline Programs↗
302
Active Trials↗
356
Companies Involved↗
Efficacy and Safety is a highly competitive landscape with 223 programs across 356 companies. The most active players are Sanofi, Haisco Pharmaceutical Group Co., Ltd., Otsuka. 104 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical44
Phase 14
Phase 271
Phase 3104
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
178 of 216 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 216 classified programs, each share of the total. Modality classified for 100% of 223 pipeline programs.
Analysis
Trial Status
2,282
clinical trials
Completed1,439 · 63%
Unknown status319 · 14%
Terminated153 · 7%
Recruiting148 · 6%
Not yet recruiting94 · 4%
Withdrawn64 · 3%
Other65 · 3%
Clinical Trials
Trial Activity
2282 trials
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06838949·80 enrolled
The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
Recruiting·—·N/A·NCT06479291·126 enrolled
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 2·NCT07275840·800 enrolled
Page 1 of 153
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)